White House Highlights UT Austin's Opioid Overdose Prevention Efforts

An image of the White House with "The White House Washington" written underneath.
March 13, 2024
The White House highlighted The University of Texas at Austin's pioneering opioid overdose prevention efforts through Operation Naloxone (now housed within UT's SHIFT initiatives) and the College of Pharmacy's PhARM Program in the Biden-Harris Administration's fact sheet for its challenge to save lives from overdose.

Summer Programs of Innovation and Diversity

LEADER/PEPP Program participants and leaders sitting together at an outdoor table for lunch.
September 6, 2022
This summer, the office of Diversity, Equity, Accessibility, and Inclusion (DEAI), hosted two intensive summer research programs: Project Engage Pharmacy Program (PEPP) Camp and the Leadership Through Engagement For the Advancement of Diverse Educational Research (LEADER) Program.

Pharmacists: The Most Accessible Healthcare Provider, Unless You Have a Substance Use Disorder

White pill bottle with white pills on a black background.
August 23, 2022
P4 students, Megan Yeung, Kami Johnston and Morgan Murchison co-author a peer-reviewed blog in Pulses encouraging educators to adapt to reflect the specific needs of people who use drugs and patients with substance use disorders. This blog also highlights UT Pharmacy as a U.S. leader in substance use disorder and harm reduction education for Pharm.D. students.

PharmE3D Labs Earn National and International Accolades

Brick facade of Pharmacy building with affixed text, "The University of Texas at Austin College of Pharmacy"
July 11, 2022
Researchers in UT Pharmacy's Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs have earned a bevy of national and international awards for their work in pharmaceutical drug delivery and 3D printing personalized medicines.

Fewer Than Half of U.S. Pharmacies Carry One of the Most Effective Drugs for Opioid Abuse

A pharmacist holding a box of medication.
June 13, 2022
Tara Law from Time writes about how few pharmacies carry buprenorphine, a life-saving drug to help treat opioid use disorder (OUD). Lucas Hill, Pharm.D., BCACP, director of the college's Pharmacy Addictions Research & Medicine (PhARM) program, offers his insight on the issue, and how the DEA's crackdown of the drug puts OUD patients at risk.

PharmE3D Labs Receive Federal Funding for 3D Printed Contraception

Four people wearing masks and lab coats.
March 14, 2022
Dr. Mo Maniruzzaman's Pharmaceutical Engineering and 3D Printing Labs have received a federal grant from the United States Agency for International Development (USAID) to develop personalized 3D printed non-hormonal intrauterine devices (IUDs). The project’s goal is to increase global access to long-term and effective contraception while minimizing some of its most debilitating side effects.

Opioid Use Disorder Paper Earns ACCP Award

A box of naloxone vials.
October 8, 2021
A paper from UT College of Pharmacy researchers was awarded the 2021 Outstanding Paper of the Year from the American College of Clinical Pharmacy (ACCP) Ambulatory Care Practice Research Network. The paper investigates the availability of buprenorphine and naloxone in Texas to treat opioid use disorder.

PharmE3D Labs Receive R01 Grant for Complex Vaccine Technologies

Three people smiling.
September 24, 2021
The College of Pharmacy’s Pharmaceutical Engineering and 3D Printing (PharmE3D) Labs recently earned a three-year $1.5 million National Institutes of Health (NIH) R01 grant to research novel manufacturing technology for complex vaccine formulations for influenza and other emerging infectious diseases.

PharmE3D Labs Earn Multiple Pharmaceutical Science Distinctions

Three men smiling.
September 10, 2021
The college's Pharmaceutical Engineering and 3D Printing (PharmE3D) labs, led by Assistant Professor in Molecular Pharmaceutics and Drug Delivery Mohammed (Mo) Maniruzzaman, Ph.D., has recently earned several national and international awards and scholarships for outstanding research contributions to the field of pharmaceutical science and technology.

Research Provides Further Insight into Causes of Manganese-Induced Parkinsonism

A man smiling in a research lab.
September 7, 2021
Somshuvra Mukhopadhyay, M.B.B.S., Ph.D., associate professor in the Division of Pharmacology and Toxicology and Hamm Centennial Fellow in Pharmacy, and a team of researchers have released new findings defining the first homeostatic regulatory pathway for manganese in mammalian systems. Identifying these pathways opens up new possible options to prevent or treat manganese-induced parkinsonism and other disorders linked to elevated manganese exposure.